Foundayo
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Foundayo?
Orforglipron tablets from Eli Lilly, FDA-approved April 2026 as the first oral non-peptide GLP-1 receptor agonist.
Patients take one tablet a day, with or without food. Its arrival matters commercially: a pill with no cold chain and no needle changes what a telehealth seller has to justify charging for.
Related reading: Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Foundayo comes up on this site
On GLP Watchdog, Foundayo comes up in 20 research articles, 50 seller reviews and 4 tools.
Research that discusses it
- Foundayo (Orforglipron) Side Effects: Rates by Dose, Dropouts and Interactions
- TrumpRx GLP-1 Prices: What Wegovy, Ozempic, Zepbound and Foundayo Cost
- Foundayo Cost: Orforglipron Price by Dose, Insurance and Medicare
- Appetite Suppressants: Every FDA-Approved Drug and What Its Label Shows
- Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On
- How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
- All 20 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers